UPDATE: Jefferies Raises Target on Incyte to $31

Jefferies raises its price target on Buy-rated Incyte INCY to $31 from $27 as Jakafi launches to an encouraging start. Jefferies comments, "INCY reported 4Q11 earnings. Jakafi end-user sales were $2m, slightly above our above-consensus $1.8m estimate. Based on management commentary, we believe certain negative one-time factors in 4Q bode well for 1Q Jakafi demand. We believe the Street continues to underappreciate the launch of Jakafi in myelofibrosis and the rest of the pipeline, including INCB28050 in rheumatoid arthritis." INCY closed at $18.27 a share yesterday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetReiterationPre-Market OutlookAnalyst RatingsJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!